Key Transaction Details
The Board of Directors of Alivus Life Sciences Limited, at its meeting held on August 18, 2026, approved a share purchase agreement to acquire 76% stake in IQGEN-X Pharma Private Limited for an aggregate approximate consideration of ₹9.12 crores, subject to adjustment as per the share purchase agreement.
Target Company Information
IQGEN-X Pharma Private Limited
- Authorized share capital: ₹2,00,00,000 divided into 20,00,000 equity shares of ₹10 each
- Incorporation: October 2016 under Companies Act 2013
- Business: Formulation development of Oral Solids, Sterile Injectables, and Ophthalmic solutions for regulated and semi-regulated markets
- Country presence: India
Financial Performance of Target
- FY 2025-26 turnover: ₹348.0 lakhs
- FY 2024-25 turnover: ₹318.2 lakhs
- FY 2023-24 turnover: ₹267.5 lakhs
Acquisition Structure
- Percentage acquired: 76% of paid-up equity share capital
- Number of shares: 8,60,589 equity shares of face value ₹10 each
- Consideration: Cash payment of approximately ₹9.12 crores
- Nature: Not a related party transaction, no promoter interest in target entity
Strategic Rationale
The acquisition provides a wider spectrum for the company to offer complete end-to-end solutions to customers in both API and CDMO space.
Regulatory Aspects
- No governmental or regulatory approvals required
- Disclosure made pursuant to SEBI circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026
Timeline and Conditions
Indicative completion timeline: December 6, 2026, or such date as may be agreed by the acquirer from execution of Share Purchase Agreement (SPA), subject to fulfilment of Conditions Precedent in the SPA.
The SPA provides that if Conditions Precedent are not met within the specified timelines from execution, the sellers will enter into a Business Transfer Agreement with the company whereby the entire business will be acquired by the company from IQGEN-X Pharma Private Limited, including employees and assets.